Method of treating cancer using
Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.
1. A method of treating cancer in a subject comprising administering to the subject an effective amount of a bacterial composition comprising Bifidobacterium animalis ssp. lactis Strain A (ATCC Deposit Number PTA-125097) to treat the cancer.
2. The method of claim 1 , wherein the cancer is a non-small cell lung cancer.
3. The method of claim 1 , wherein the cancer is a colorectal cancer.
4. The method of claim 1 , wherein the cancer is a triple negative breast cancer.
5. The method of claim 1 , wherein the cancer is a bladder cancer.
6. The method of claim 1 , wherein the cancer is a gastroesophageal cancer.
7. The method of claim 1 , wherein the cancer is a renal cell carcinoma.
8. The method of claim 1 , wherein the cancer is a solid tumor.
9. The method of claim 1 , wherein the bacterial composition is administered orally.
10. The method of claim 1 , wherein the bacterial composition is formulated as a capsule or a tablet.
11. The method of claim 1 , wherein the bacterial composition comprises at least 7.5×10 10 colony forming units (CFUs) of Bifidobacterium animalis ssp. lactis.
12. The method of claim 1 , wherein the bacterial composition is administered at least once daily.
13. The method of claim 1 , wherein the bacterial composition is administered twice daily.
14. The method of claim 1 , wherein the bacterial composition is administered in two or more doses.
15. The method of claim 1 , wherein the method further comprises administering to the subject a second cancer therapy.
16. The method of claim 15 , wherein the second cancer therapy is administered once every 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
17. The method of claim 15 , wherein the second cancer therapy comprises cancer immunotherapy.
18. The method of claim 17 , wherein the cancer immunotherapy comprises administering an immune checkpoint inhibitor to the subject.
19. The method of claim 18 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
20. The method of claim 19 , wherein the anti-PD-1 antibody is nivolumab.
21. The method of claim 19 , wherein the anti-PD-1 antibody is pembrolizumab.
22. The method of claim 21 , wherein pembrolizumab is administered intravenously.
23. The method of claim 18 , wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
24. The method of claim 23 , wherein the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab.
25. The method of claim 23 , wherein the anti-PD-L1 antibody is administered intravenously.
26. The method of claim 18 , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
27. The method of claim 26 , wherein the anti-CTLA-4 antibody is ipilimumab.
28. The method of claim 27 , wherein ipilimumab is administered intravenously.